2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
0
Active Trials
2
Rare Diseases
across 3 areas
0
News (30d)
Quiet
Antengene (Hangzhou) Biologics Co., Ltd. is a company with 2 orphan drug designations across 2 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| gastric cancer | antibody drug conjugate targeting Claudin 18.2 (CLDN 18.2) consisting of a humanized monoclonal antibody against CLDN 18.2 and a conjugated linker-payload VC-MMAE (maleimidocaproyl-valine-citrulline-p-aminobenzylalcohol-Monomethyl Auristatin E) | Des.TrialAppr. |
| malignant pancreatic neoplasm | Antibody drug conjugate targeting Claudin 18.2 (CLDN 18.2) consisting of a humanized monoclonal antibody against CLDN 18.2 and a conjugated linker-payload VC-MMAE (maleimidocaproyl-valine-citrulline-p-aminobenzylalcohol-Monomethyl Auristatin E) | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
27
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
27
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio